Olsalazine Sodium

Sold as Dipentum. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Olsalazine Sodium (sold as Dipentum), first approved Jul 31, 1990, with 0 new uses approved and 0 published complete response letters.

First approved: Jul 31, 1990
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $2.9M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Dipentum	Part D	$2.9M	+1%	188

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

DIPENTUM 250 MG CAPSULE: $15.70 per unitBrand · +5% in a year

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Jul 31, 1990	DipentumNDA 19715 · New molecular entity	Mylan Spclt Viatris	31	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA